Orally effective CVS-1123 prevents coronary artery thrombosis in the conscious dog

Circulation

Volumn 94, Issue 7, 1996, Pages 1705-1712

  Cousins, Geoffrey R ^a   Friedrichs, Gregory S ^a   Sudo, Yuji ^a   Rebello, Sam S ^a   Rote, William E ^b   Vlasuk, George P ^b   Nolan, Thomas G ^b   Mendoza, Christine ^b   Lucchesi, Benedict R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Dendreon   (United States)

Author keywords

electrical stimulation; ischemia; myocardial infarction; platelets; thrombosis

Indexed keywords

CVS 1123; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

EID: 0029778319     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.7.1705     Document Type: Article

References (33)

1. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: interaction, maintenance and regulation. Biochemistry. 1991;30:10363-10370.
2. Badimon L, Badimon JJ, Lassila R, Heras M, Chesebro JH, Fuster V. Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: effects of hirudins, heparin and calcium chelation. Blood. 1991;78:423-434.
3. Coughlin SR. Thrombin receptor function and cardiovascular disease. Trends Cardiovasc Med. 1994;4:77-83.
4. Hilpert K, Ackermann J, Banner DW, Gast A, Gubernator K, Hadvary P, Labler L, Muller K, Schmid G, Tschopp T, Waterbeemd H. Design and synthesis of potent and highly selective thrombin inhibitors. J Med Chem. 1994;37:3889-3901.
5. Davey M, Luscher E. Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature. 1967;216:857-858.
6. Fenton JW. Regulation of thrombin generation and functions. Semin Thromb Hemost. 1988;14:234-240.
7. Coughlin SR, Vu T-KH, Hung DT, Wheaton VI. Characterization of the cloned platelet thrombin receptor: issues and opportunities. J Clin invest. 1992;89:351-355.
8. Weksler BB, Ley CW, Jaffe EA. Stimulation of endothelial cell prostacyclin by thrombin, trypsin, and the ionophore A23187. J Clin Invest. 1982;62:923-930.
9. Prescott SM, Zimmerman GA, McIntyre TM. Human endothelial cells in culture produce platelet-activating factor when stimulated by thrombin. Proc Nail Acad Sci USA. 1984;81:3534-3538.
10. Camps M, Carozzi A, Schnabel P, Scheer A, Parker PJ, Gierschik P. Isozyme-selective stimulation of phospholipase C-β2 by G protein βγ-subunits. Nature. 1992;360:684-686.
11. Daniel TO, Gibbs VC, Milfay DF, Garavoy M, Williams LT. Thrombin stimulates c-sis gene expression in microvascular endothelial cells. J Biol Chem. 1986;261:9579-9582.
12. Fenton JW II,. Ni F, Wiltting JI, Brezniak DV, Andersen TT, Malik AB. The rational design of thrombin-directed antithrombotics. Adv Exp Med Biol. 1993;340:1-13.
13. Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation. 1994;90:1522-1536.
14. Yamashita T, Yamamoto J, Sasaki Y, Matsuoka A. The antithrombotic effect of low molecular weight synthetic thrombin inhibitors, argatroban and PPACK, on He-Ne laser-induced thrombosis in rat mesenteric microvessels. Thromb Res. 1993;69:93-100.
15. Ikoma H, Ohtsu K, Tamao Y, Kikumoto R, Okamoto S. Effect of a potent thrombin inhibitor. MCI-9038, on novel experimental arterial thrombosis. Blood Vessels. 1982;13:72-77.
16. Rote WR, Dempsey EM, Oldeschulte GL, Ardecky RJ, Tamura SY, Nutt RF, Bergum PW, Tran HS, Anderson SM, Vlasuk GP. Evaluation of a novel orally active direct inhibitor of thrombin in animal models of thrombosis. Circulation. 1994;90(pt 2):I-344. Abstract.
17. Bock PE, Craig PA, Olson ST, Singh P. Isolation of human blood coagulation α-factor Xa by soybean trypsin inhibitor-sepharose chromatography and its active-site titration with fluorescein mono-p-guanidinobenzoate. Arch Biochem Biophys, 1989;273:375-388.
18. Marcus AL. Platelets and their disorders. In: Ratnoff OD, Forbes CD, eds. Disorders of Hemostasis. 2nd ed. New York, NY: WB Saunders Co; 1991:75-140.
19. Yao SK, Ober JC, Gonenne A, Clubb FJ, Krishnaswami A, Ferguson JJ, Anderson HV, Gorecki M, Buja LM, Willerson JT. Active oxygen species play a role in mediating platelet aggregation and cyclic flow variations in severely stenosed and endothelium-injured coronary arteries. Circ Res. 1993;73:952-967.
20. Kroll MH, Schafer AI. Biochemical mechanisms of platelet activation. Blood. 1989;74:1181-1195.
21. Marcus AJ, Safier LB. Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis. FASEB J. 1993; 7:516-522.
22. Lucchesi BR, Rote WE, Driscoll EM, Mu D-X. Prevention of thrombosis and rethrombosis and enhancement of the thrombolytic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist. Br J Pharmacol. 1994;113:1333-1343.
23. Callas D, Bacher P, Iqbal O, Hoppensteadt D, Fareed J. Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin. Thromb Res. 1994;74:193-205.
24. Romson JL, Haack DW, Lucchesi BR. Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of antithrombotic agents. Thromb Res. 1980;17: 841-853.
25. 2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart. J Mol Cell Cardiol 1989;21:393-405.
26. Rote WE, Nedelman MA, Mu DX, Manley PJ, Weisman H, Cunningham MR, Roncinske RA, Frelinger AL III, Lucchesi BR. Chimeric 7E3 prevents carotid artery thrombosis in cynomolgus monkeys. Stroke. 1994;25:1223-1232.
27. Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation. 1994;89:1802-1809.
28. Shebuski RJ, Stabilito IJ, Sitko GR, Polokoff MH. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis. Circulation. 1990;82:169-177.
29. Werns SW, Rote WE, Davis JH, Guevara T, Lucchesi BR. Nitroglycerin inhibits experimental thrombosis and reocclusion after thrombolysis. Am Heart J, 1994;127:727-737.
30. Lynch JJ Jr, Sitko GR, Mellott MJ, Nutt EM, Lehman ED, Friedman PA, Dunwiddie CT, Vlasuk GP. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy: a comparison of factor Xa versus thrombin inhibition. Cardiovasc Res. 1994;28:78-85.
31. Scharfstein JS, Loscalzo J. Molecular approaches to antithrombotic therapy, Hosp Pract. 1992;27:77-86.
32. Yasuda T, Gold HK, Fallen JT, Leinbach RC, Guerrero JL, Scudder LE, Kanke M, Shealy D, Ross MJ, Collen D, Coller BS. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest. 1988;81: 1284-1291.
33. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J, Clot-bound thrombin is protected from inhibition by heparin-antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.